Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of elranatamab + daratumumab + lenalidomide versus daratumumab + lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
MOH_2023-08-17_012886Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Jun 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elranatamab in multiple myeloma (MM) (2 arms), sponsored by Pfizer. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2023-08-17_012886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-17_012886.